LIFECORE BIOMEDICAL, INC. Finance Lease, Right-of-Use Asset, before Accumulated Amortization
LIFECORE BIOMEDICAL, INC. (LFCR) had Finance Lease, Right-of-Use Asset, before Accumulated Amortization of $4.10 million as of 2024-05-26, per its 10-K filed 2024-08-26.
Discontinued › Notes › Leases › Finance Lease, Right-of-Use Asset, after Accumulated Amortization
us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization · last filed 2024-08-26
- 2024-05-26: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $4.10M.
- 2023-05-28: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $3.90M.
- 2022-05-29: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $3.80M.
- 2021-05-30: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $3.80M.
| Period end | Finance Lease, Right-of-Use Asset, before Accumulated Amortization |
|---|---|
| 2024-05-26 | $4.10M 10-K · filed 2024-08-26 |
| 2023-05-28 | $3.90M 10-K · filed 2024-08-26 |
| 2022-05-29 | $3.80M 10-K · filed 2024-03-20 |
| 2021-05-30 | $3.80M 10-K/A · filed 2023-03-16 |
| 2020-05-31 | $3.80M 10-K · filed 2021-07-29 |
| 2019-05-26 | $3.80M 10-K · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |